Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis

Journal of Clinical Investigation

Volumn 104, Issue 11, 1999, Pages 1517-1525

  Chen, Lin ^a   Adar, Rivka ^b   Yang, Xiao ^a   Monsonego, Efrat O ^b   Li, Culling ^a   Hauschka, Peter V ^c   Yayon, Avner ^b   Deng, Chu Xia ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; FIBROBLAST GROWTH FACTOR RECEPTOR; GLYCINE; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN;

ACHONDROPLASIA; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE DYSPLASIA; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; MACROCEPHALY; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0033456159     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6690     Document Type: Article

References (45)

1. Gilbert, S.F. 1994, The development of bones. In Developmental biology. 4th edition. S.F. Gilbert, editor. Sinauer Associates. Sunderland, MA. 333-338.
2. Horton, W.A. 1997. Fibroblast growth factor receptor 3 and the human chondrodysplasias. Curr. Opin. Pediatr. 9:437-442.
3. Muenke, M., and Schell, U. 1995. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet. 11:308-313.
4. Mulvihill, J.J. 1995. Craniofacial syndromes: no such thing as a single gene disease. Nat. Genet. 9:101-103.
5. Rousseau, F., et al. 1994. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 371:252-254.
6. Shiang, R., et al. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 78:335-342.
7. Tavormina, P.L., et al. 1997. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibrobtast growth factor receptor 3. Nat. Genet. 9:321-328.
8. Bellus, G.A., et al. 1995. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat. Genet. 10:357-359.
9. Oberklaid, F., Danks, D.M., Jensen, F., Stace, L., and Rosshandler, S. 1979. Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. J. Med. Genet. 16:140-146.
10. Superti-Furga, A., et al. 1995. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur. J. Pediatr. 154:215-219.
11. Wang, Y., et al. 1999. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor. Proc. Natl. Acad. Sci. USA. 96:4455-4460.
12. Naski, M.C. Colvin, J.S., Coffin, J.D., and Ornitz, D.M. 1998. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development. 125:4977-4988.
13. Webster, M.K., and Donoghue, D.J. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15:520-527.
14. Li, Y., Mangasarian, K., Mansukhani, A., and Basilico, C. 1997. Activation of FGF receptors by mutations in the transmembrane domain. Oncogene. 27:1397-1406.
15. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 84:911-921.
16. Yang, X., Li, C., Xu, X., and Deng, C. 1998. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc. Natl. Acad. Sci. USA. 95:3667-3672.
17. Lakso, M., et al. 1996. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl. Acad. Sci. USA. 93: 5860-5865.
18. Albrecht, U., Eichele, G., Helms, J.A., and Lu, H-C. 1997. Visualization of gene expression patterns by In Situ hybridization. In Molecular and cellular methods in developmental toxicology. George P. Daston, editor. CRC Press. Boca Raton, FL. 49-69.
19. Ornitz, D.M., and Leder, P. 1992. Ligand specificity and dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem. 267:16305-16311.
20. Deng, C.,Thomas, K.R., and Capecchi, M.R. 1993. Location of crossovers during gene targeting with insertion and replacement vectors. Mol. Cell. Biol. 13:2134-2140.
21. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G., and Ornitz, D.M. 1996. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet. 12:390-397.
22. Su, W.C., et al. 1997. Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature. 386:288-292
23. Li, C., et al. 1999. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 8:35-44.
24. Sahni, M., et al. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13:1361-1366.
25. Neilson, K.M., and Friesel, R.E. 1995. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J. Biol. Chem. 270:26037-26040.
26. Neilson, K.M., and Friesel, R. 1996. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains. J. Biol. Chem. 271:25049-25057.
27. Robertson, S.C., et al. 1998. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc. Natl. Acad. Sci USA. 95:4567-4572.
28. Galvin, B.D., Hart, K.C., Meyer, A.N., and Webster, M.K. 1996. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. Proc. Natl. Acad. Sci. USA. 93:7894-7899.
29. Park, W.J., et al. 1995. Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am. J. Hum. Genet. 57:321-328.
30. Coffin, J.D., et al. 1995. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell. 6:1861-1873.
31. Carlton, M.B., Colledge, W.H., and Evans, M.J. 1998. Crouzon-like craniofacial dysmorphology in the mouse is caused by an insertional mutation at the Fgf3/Fgf4 locus. Dev. Dyn. 212:242-249.
32. Wilkie, A.O., Morriss-Kay, G.M., Jones, H.Y., and Heath, J.K. 1995. Functions of fibroblast growth factors and their receptors. Curr. Biol. 5:500-507.
33. Givol, D., and Yayon, A. 1992. Complexity of FGF receptors: genetic basis tor structural diversity and functional specificity. FASEB J. 6:3362-3369.
34. Karaplis, A.C., et al. 1994. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev. 8:277-289.
35. Lanske, B., et al. 1996. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science. 273:663-665.
36. Vortkamp, A., et al. 1996. Regulation of rare of cartilage differentiation by Indian hedgehog and PTH-related protein. Science. 273:613-622.
37. Erlebacher, A., Filvaroff, E.H., Gitelman, S.E., and Derynck, R. 1995. Toward a molecular understanding of skeletal development. Cell. 80:371-378.
38. Komori, T., and Kishimoto, T. 1998. Cbfa1 in bone development. Curr. Opin. Genet. Dev. 8:494-499.
39. Komori, T., et al. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts Cell. 89:755-764.
40. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L., and Karsenty, G. 1997. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 89:747-754.
41. Lian, J.B., Stein, G.S., Stein, J.L., and van Wijnen, A.J. 1998. Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. J. Cell. Biochem. Suppl. 30-31:62-72.
42. Denhardt, D.T., and Noda, M. 1998. Osteopontin expression and function: role in bone remodeling. J. Cell. Biochem. Suppl. 30-31:92-102.
43. Nakase, T., et al. 1994. Alterations in the expression of osteonectin, osteopontin and osteocalcin mRNAs during the development of skeletal tissues in vivo. Bone Miner. 26:109-122.
44. Cancedda, R., Descalzi Cancedda, F., and Castagnola, P. 1995. Chondrocyte differentiation. Int. Rev. Cytol. 159:265-358.
45. Ducy, P., et al. 1996. Increased bone formation in osteocalcin-deficient mice. Nature. 382:448-452.